Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCT-601 Monotherapy and Combination in Advanced Solid Tumors
NCT05389462Phase 1Terminated
- Sponsor
- ADC Therapeutics
- Start
- Jul 2022
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of mipasetamab uzoptirine in soft tissue sarcoma (STS), bone sarcoma, non-small cell lung cancer (NSCLC) and 2 more (4 arms), sponsored by ADC Therapeutics. Primary endpoints: Safety and Tolerability as Assessed by Number of Participants with Adverse Events, Number of Participants who Experience a Dose Limiting Toxicity and 2 more. Started Jul 2022; status: terminated.
02
Drugs
mipasetamab uzoptirine
03
Conditions
soft tissue sarcoma (STS)bone sarcomanon-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)solid tumor
Beyond the preview
Go deeper on NCT05389462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05389462.